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Magnetic Microcapsules As Novel
Biomonitors of Cross-Linking Agents and
Diet-Dependent Reactive Oxygen
Species in the Human Gastrointestinal
Tract
by Sheila A. Bingham,' Atul B. Shah,' Anne
Ellul,2John H. Cummings,' and Ian K. O'Neill2
Sixhealthy, scientifically informedhuman volunteers weregiven"C-labeledpolyethyleneimine(PEI)microcapsules
by mouth. Fecal "4C recovery wasinverselyrelatedtomeanguttransittime (r = -0.66), andtheextentofcross-linking
betweenthemembraneandcorePEIwasinversely relatedtototalfecaloutput(r = -0.81).Cross-linkingofPEImicrocap-
sulesmay beabiomonitorofendogenouscross-linkingagentswithinthehumangastrointestinal tract. Extensivelossof
[4CWCH3 labeloccurdfromthemicrocapsulesduringhumantrnst and in vitrofermentations withhumanfecalflora.
Amechanismwhereby reactiveoxygenspeciescouldariseintheiron-richcoreofthesemicrocapsules, leadingtolossof
['4CJCH3 label, is proposed.
Introduction
The importance of diet (1) and the high contribution from
gastrointestinal (GI) sitestohuman cancerrisk(2), haveprompt-
ed us to devise abiomonitoringtechnique fortheGIcavity (3).
This system consists of an oral dose of aqueous suspension of
millions of magnetically recoverable, semipermeable micro-
capsules with atough nylon membraneenclosing apolyamine,
polyethyleneimine (PEI). Previous studies in rodentshave shown
that PEI microcapsules trapped alkylating agents (4), N-
nitrosating agents (5), mutagens/carcinogens having planar
molecular structure (6,7), and bifunctional alkylating (cross-
linking) agents (8). Forthe firsttime, wehaveusedthesemicro-
capsules as biomonitors in healthy free-living humans.
Methods
Semipermeable, magnetic microcapsules with a membrane
consistingofpolyhexamethylenediamineterephthalamide grafted
on to polyethyleneimine (M.W. 50,000) were prepared under
modified conditions to that reported previously (3) so as to
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have a larger diameter and were sieved several times through
25-pm and then 50-Am sieves in order to remove smaller
microcapsules. A50-mLsuspension inethanol wastreatedwith
[14CJCH3I inethanol (100uCi, 56mCi/mmole) overnightwith
shaking at37°C, washedseveraltimes, andthendiluted to 26.4
kBq/mL, measured by suspension in scintillation fluid. Full
details will be reported elsewhere (9).
One milliliter ofthe '4C-labeled microcapsules was diluted
with 3 mL ethanol, transferred to gelatin capsules, and ad-
ministered to six healthy, nonsmoking, scientifically informed
subjects(fivemen, onewoman, agerange26-59years), together
with200radio-opaque markers (ROM) (10), also ingelatincap-
sules. Baseline spoturines and stoolspecimens were collected
by all the subjects immediately before administration of the
microcapsules. After taking the microcapsules, subjects col-
lected all fecal specimens, which were X-rayed to count the
ROM, until all ROM had been recovered, and for a further 3
days. Urine samples were collected for 4-6 days and were
checked for their completeness using p-aminobenzoic acid
(PABA) (11).
Fecal samples were individually digested with 10% aqueous
Tweensolutionfor 1 hr, andaliquots wereremovedfor'4Ccoun-
ting after sample oxidation. Microcapsules were removed
magnetically fromtheremainingfecalhomogenateandstoredin
ethanol at room temperature until analysis.
Forestimationofcross-linking, a 100jALaliquotofmicrocap-
sules wasdilutedwith waterto 1.0mLandthemembranes rup-BINGHAMETAL.
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FIGURE 1. Net 14C fecal excretion (percent ofadministered dose in micro-
capsules) in relation to transit time ofradio-opaque markers (hours).
turedby an ultrasonicatorwithTiprobe(four 15-secperiodswith
ice cooling), as reported previously (8). From the resulting
suspension, a 100-1.Laliquot wastaken to measuretotal radioac-
tivity (core and membrane) and the remainder centrifuged to
separatefor 14Ccountingthe core(supernatant) andmembrane
(pellet) fractions. The extent ofcross-linking ofmicrocapsule
core PEI to membrane PEIby endogenous agents wasassessed
from alteration relative to analiquotofunused (control) micro-
capsules ofthe ratio:
(membrane "4C)
(core 14C + membrane "4C)
To assess "4C loss of radioactivity, ethanol suspensions of
microcapsules removed from feces werediluted with waterand
aliquots taken for Coulter counter assay and scintillation count-
ing in Aquasol, so as to obtain their specific activity (dpm/-
million). Results were compared with unused (control)
microcapsules.
Results
Complete recovery ofROM was found fromeach subject(99
+ 1%; range 196-200). The meantransittimeofROM through
the gut (MTT) ranged from 26 hr in subject 5 to 106 hr in sub-
ject 3, and theradioactivity in individual fecal samples correlated
well (r = 0.96) with the number ofROM recovered. In the last
fecal samplefrom each volunteer (usuallyday 10), themeasured
radioactivity was atthebaseline levelsofthepreadministration
control fecal sample.
Recoveryofradioactivity inthefeces was 88 + 5% ofthead-
ministereddoseandvariedbetweensubjects. The recovery of14C
dose in feces was inversely related to MTTthrough the gut(r =
-0.66; Fig. 1). Eighteen out of20 samples were complete by
PABA analysis and there was no detectable "4C in urine.
Microcapsules recovered from human feces and counted by
scintillationcounting showed significant removal of[14C]CH3
label, ranging between 29 and 81%. Label cleavagefrom micro-
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FIGURE 2. Cross-linking inmicrocapsules in relationtototal fecal output dur-
ing the period ofmicrocapsule excretion.
capsules wasunrelatedtothetotal "Cfecal recovery (r = 0.23)
andtoMTT(r = 0.19). Comparisonoflosses formicrocapsules
on several consecutive days of excretion did not reveal any
systematic increase oflabel losswithlongerGIresidence. There
was no effect of length of time ofGI residence on the size of
microcapsules recovered fromconsecutive fecal samples.
Inaddition, the ratio (membrane '4C/total '4C) was increased
morethan5-fold(from6.8to <35), i.e., atleastone-thirdofcore
PEIinthemicrocapsules hadbecomecross-linkedtothemem-
branebyendogenous agentsaftertransitthrough thegut. After
correcting the cross-linking calculation for label loss in each
specimen and correcting for the number of microcapsules
recovered ineach fecal specimen, cross-linking wasfoundtobe
significantlyand inversely related tostool weight, (r = -0.78)
and to total fecal output (r = -0.81) (Fig. 2). There were no
significantassociationsbetweencross-linkingandtransittime,
norbetween label loss and any colonic factor.
Discussion
There has been no previous method for monitoring reactive
substances inthelowerGItractwhereuniquebiological condi-
tions pertain, and it is perhaps notsurprising thatnovel results
were obtained fromthis first use ofmicrocapsules. It is shown
that these microcapsules can be passed through the human GI
tract with a similartransit time to inertradio-opaque markers.
The unchanged size distribution and lack of effect of gut
residence time on microcapsule sizedistribution in successive
stools areconsistentwiththerebeing nopreferential GI retention
ofsmaller microcapsules.
Thefindings ofsubstantialcleavageofcovalentlybound label
fromallmicrocapsules recovered fromvolunteerswassurprise
ing. Cleavageispresumedtooccurinthecolonbecauseanaero-
bic incubation ofmicrocapsules with mixed human fecal flora
alsodemonstrated asubstantiallossofthe 14C label (9). Lossof
label has notbeenfound in ratsfedchow, buthas been found in
ratsfedhumandiets, highinmeat, fatandlowindietaryfiber(9).
MicrocapsulestreatedwithH202alsolose "4C, exclusively from
the core (8). This effect is presumed to arise by OH radical
hydrogen atom abstraction from the ['4CJCH3 label or PEI
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molecule leading to production offormaldehyde (hydrate) ora
low molecularweightPEIfragment, whichwoulddiffuseoutof
the microcapsules and be incorporated into gut microfloral
metabolism. Such incorporation would account for both the
relatively high 14C excretioninfecesandcorrelationwithROM
excretion, despite most['4C]CH3 labelbeing removedfromthe
microcapsules in male volunteers. The origin ofthis label loss
mustbe substancesoflowmolecularweightabletopassthrough
the semipermeable membranes ofthe microcapsules (i.e., not
enzymes or bacteria). That the mechanism then involves OH
radical formation is suggested by theapparentiron-dependent ef-
fects in microcapsules of H202 in vitro (8) and by the many
known substances undergoing Fentonreaction toproduce OH
radicals. The unique structure ofthese microcapsules contain-
ing finely divided Fe3O4 and mobile ['4C]CH3- labeled PEI
chains incloseproximity shouldprovideanespecially favorable
opportunity for such reactions to occur.
In in vitro studies, the endogenous DNA-damaging agents
fecapentaene-12 and 4-hydroxynonenal were shown to cause
cross-linking in microcapsules (8). The finding ofsubstantial
cross-linking after GI transit through humans indicates the
presenceofendogenouscross-linkingagents within thehuman
GI tract. Colon cancer risk is inversely associated with fecal
weight in human populations, and there isasignificant inverse
relationship between cross-linking and fecal bulkfound in this
study (r = -0.81; Fig. 2). This, andtheabsenceofarelationbe-
tweencross-linking andtransittime, would suggestthatcross-
linking is related to proximity between the microcapsules and
suspect cross-linking agents within the gastrointestinal tract,
ratherthanextendedlengthoftimeofresidencewithinthetract.
A similar inverse relationship was found also between ben-
zo[a]pyrenemetabolitetrappingandfecalbulkinF344rats(12).
This manuscript waspresented asaposterattheConferenceonBiomonitor-
ing and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that washeld in Kailua-Kona, Hawaii, 26
October-I November 1991.
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